• DNA, Protein Analyses Improve Diagnosis of Unusual Epidermolysis Bullosa Cases, Study Shows
  • Rare Disease Groups, Patients Differ on ‘Right to Try’ Bill Before US Congress
  • Diacerein Cream Shows Promise in Reducing Blisters in EBS Patients, Trial Shows
  • Study Finds New Gene Mutation Leading to Recessive Dystrophic Epidermolysis Bullosa
  • FDA Allows Pediatric Enrollment in Phase 1/2 Trial of FCX-007 Gene Therapy for RDEB
  • NORD Fundraiser Sets 7,000-Mile ‘Bike, Run or Walk’ Goal for 7,000 Rare Diseases
  • Abeona’s Gene Therapy EB-101 Receives FDA’s Regenerative Medicine Advanced Therapy Designation
  • Rare Hair Loss Condition Linked to PLEC Gene Mutation and EBS Subtype for Only 2nd Time
  • Factors Beyond COL7A1 Mutations May Contribute to Dystrophic EB Forms, Study Suggests
  • Krystal Biotech Issued Patent Related to KB103 for Dystrophic EB
  • Phase 2 Trial Data Validate New Investigator’s Global Assessment Scale
  • Bactroban-resistant Bacteria Commonly Found in Skin Wounds of EB Patients, Study Shows